Shares of Novartis AG (NYSE:NVS) have been assigned a consensus recommendation of “Hold” from the nineteen brokerages that are presently covering the firm. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $80.42.

A number of analysts have recently commented on the company. Vetr upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $79.30 target price on the stock in a research note on Wednesday, March 1st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, March 14th. Barclays PLC assumed coverage on Novartis AG in a research note on Tuesday, March 7th. They issued an “underweight” rating on the stock. Societe Generale upgraded Novartis AG from a “hold” rating to a “buy” rating and upped their target price for the stock from $73.82 to $74.37 in a research note on Tuesday, March 7th. Finally, BNP Paribas downgraded Novartis AG from a “neutral” rating to an “underperform” rating in a research note on Tuesday, March 7th.

Novartis AG (NYSE:NVS) traded down 0.5590% during trading on Tuesday, reaching $72.9201. The company’s stock had a trading volume of 1,465,439 shares. Novartis AG has a one year low of $66.93 and a one year high of $83.58. The firm has a market capitalization of $173.12 billion, a P/E ratio of 26.0429 and a beta of 0.73. The stock has a 50-day moving average of $74.85 and a 200 day moving average of $73.45.

Novartis AG (NYSE:NVS) last issued its earnings results on Wednesday, January 25th. The company reported $1.12 EPS for the quarter, hitting analysts’ consensus estimates of $1.12. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. The firm had revenue of $12.32 billion for the quarter, compared to the consensus estimate of $12.44 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. The company’s revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts predict that Novartis AG will post $4.69 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Novartis AG (NVS) Given Average Rating of “Hold” by Analysts” was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at http://www.dailypolitical.com/2017/04/18/novartis-ag-nvs-given-average-rating-of-hold-by-analysts.html.

A number of institutional investors have recently modified their holdings of the company. Dodge & Cox acquired a new position in shares of Novartis AG during the fourth quarter worth about $3,330,137,000. The Manufacturers Life Insurance Company acquired a new position in shares of Novartis AG during the third quarter worth about $304,776,000. Franklin Resources Inc. increased its position in shares of Novartis AG by 16.4% in the fourth quarter. Franklin Resources Inc. now owns 14,753,570 shares of the company’s stock worth $1,074,650,000 after buying an additional 2,074,452 shares in the last quarter. Federated Investors Inc. PA increased its position in shares of Novartis AG by 3,276.1% in the fourth quarter. Federated Investors Inc. PA now owns 1,907,815 shares of the company’s stock worth $138,965,000 after buying an additional 1,851,305 shares in the last quarter. Finally, CGOV Asset Management purchased a new position in shares of Novartis AG during the third quarter worth approximately $82,650,000. Institutional investors own 9.82% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.